Terug naar bedrijfspagina

Nieuws over Oxurion (ThromboGenics)

15/10/2020 Oxurion - Business Update – Q3 2020 (15.10.2020)

18/09/2020 Oxurion - Business Update - H1 2020 (17.9.2020)

01/09/2020 Oxurion - Reports First Patient Dosed in Phase 2 study evaluating THR-149 f (1.9.2020)

03/08/2020 Oxurion - appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer (3.8.2020)

03/08/2020 Oxurion NV - appoints Grace Chang as Chief Medical Officer (3.8.2020)

07/05/2020 Oxurion NV Business Update - Q1 2020 (7.5.2020)

13/03/2020 Oxurion NV Business Update – FY 2019 (13.3.2020)

07/01/2020 Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME

18/10/2019 Oxurion - Business Update Q3 (18.10.2019)

09/10/2019 Oxurion-Poster Presentation Featuring Positive Topline data from Phase 1 Trial(9.10.2019)

05/09/2019 Oxurion NV Business Update – H1 2019 (5.9.2019)

02/09/2019 Oxurion - late-breaker presentation of topline THR-149 Phase 1 clinical data at EURETINA (2.9.2019)

21/08/2019 Oxurion wordt voetje gelicht door testdata (KBC)

20/08/2019 Oxurion - Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME (20.8.2019)

06/06/2019 Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting (6.6.2019)

08/05/2019 Oxurion NV - business update Q1 2019 (8.5.2019)

24/04/2019 Oxurion NV - full enrollment Phase 1 trial THR149 (24.04.2019)

04/04/2019 Oxurion-full enrollment Phase 2 of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME (4.4.2019)

07/03/2019 Oxurion NV Business Update – FY 2018 (7/03/19)

06/02/2019 Oxurion (LifeSci)